

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	10/559,982
				<b>Filing Date</b>	February 2, 2006
				<b>First Named Inventor</b>	Ruggero Fariello
				<b>Group Art Unit</b>	1617
				<b>Examiner Name</b>	Sahar JAVANMARD
<b>Confirmation No.</b>	6583				
<b>Attorney Docket No.</b>	373987-011US (102895)				
Sheet	1	of	1		

U.S. PUBLISHED DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Publication Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	A10	US-5,502,079		Dostert <i>et al.</i>	03-26-1996

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>2</sup>	
		Office	Number			Kind Code (if known)	Yes
	B1						

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>2</sup>		
			Yes	No	
	C106	ANONYMOUS: "Newron Releases Positive Preliminary Phase II Data for Salfinamide in Parkinson's Disease" PRESS RELEASE OF 01-09-2003, Retrieved from the Internet: <URL: <a href="http://www.newron.com/uploads/SalfinamidePhaseIIdataFinal090103.pdf">http://www.newron.com/uploads/SalfinamidePhaseIIdataFinal090103.pdf</a> retrieved on 02-18-2009			
	C107	Chazot, P., 2001, "Salfinamide, Newron Pharmaceuticals," <i>Current Opinion in Invest. Drugs</i> , 2(6): 809-813			
	C108	Maj, R. <i>et al.</i> , 1999, "PNU-141774E, A Combined MAO-B and Glutamate Release Inhibitor, is Effective in Animal Models of Parkinson's Disease," <i>Society for Neuroscience</i> , Vol. 25, p. 1599			

15107351.1.BUSINESS

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.